Published online before print June 27, 2002, doi: 10.1161/01.RES.0000027562.91075.56
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 28, 2001
Revised on June 6, 2002
Accepted on June 11, 2002
Cyclophilin-Mediated Pathways in the Effect of Cyclosporin A on Endothelial Cells. Role of Vascular Endothelial Growth Factor
M. Victoria Alvarez-Arroyo ;
From the Laboratorio de Nefrología-Hipertensión (M.V.A.-A., S.Y., S.J., F.R.G.-P., M.A.C., J.J.P.D., C.C.), Fundación Jiménez Díaz, Universidad Autónoma, Instituto Reina Sofía de Investigación Nefrológica, Madrid, Spain; Wenger CHEMTECH (R.M.W.), Riehen, Switzerland; and the Molecular and Cell Biology Department (D.S.P.), ImClone Systems Inc, New York, NY.
* To whom correspondence should be addressed. E-mail: ccaramelo{at}fjd.es.
The relative importance of cyclophilin (CyP) versus calcineurin (Cn)-mediated mechanisms in the effect of cyclosporin A (CsA) on endothelial cells (ECs) is largely unknown. In cultured ECs, CsA was cytotoxic/proapoptotic or cytoprotective/antiapoptotic at high or low concentrations, respectively. CsA analogs (MeVal-4-CsA and MeIle-4-CsA), which bind to CyP but do not inhibit Cn, closely reproduced the CsA effects. Based on our previous data, the role of vascular endothelial growth factor (VEGF) as a mediator of CsA-induced cytoprotection was further analyzed. The actions of CsA and CsA analogs were shifted from a protective to a cell-damaging pattern in the presence of a specific anti-VEGF monoclonal antibody (mAb). This positive interaction was further supported by a transient increase in cytosolic free calcium concentration ([Ca2+]i) by VEGF after pretreatment with either CsA or MeVal-4-CsA and an increase in the expression and synthesis of VEGF receptor 2 (VEGFR2). Of functional importance, blockade of the interaction between VEGF and VEGFR2 by a VEGFR2 mAb abolished the cytoprotective effect of CsA. In addition, preconditioning with low concentrations of CsA or CsA analogs increased both cytoprotection and VEGFR2 mRNA expression when EC were exposed to higher concentrations of CsA. In summary, our results reveal that (1) the biphasic responses to CsA in EC are related to the interaction of CsA with CyP rather than with Cn and (2) VEGF is a critical factor in the cytoprotective effect of CsA, by a mechanism that involves VEGFR2.
Key words: cyclosporin A • cyclophilin • cyclophilin-binding analogs • vascular endothelial growth factor • vascular endothelial growth factor receptor 2 • cytoprotection
This article has been cited by other articles:
 |
|
 |
|
  S. Perez and V. Weis Cyclophilin and the Regulation of Symbiosis in Aiptasia pallida Biol. Bull., August 1, 2008; 215(1): 63 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Du, W.-H. Zhou, L. Dong, X.-Y. Zhu, Y.-Y. He, J.-Y. Yang, and D.-J. Li Cyclosporin A Promotes Growth and Invasiveness In Vitro of Human First-Trimester Trophoblast Cells Via MAPK3/MAPK1-Mediated AP1 and Ca2+/Calcineurin/NFAT Signaling Pathways Biol Reprod, June 1, 2008; 78(6): 1102 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Crist, D. L. Sprague, and T. L. Ratliff Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes Blood, April 1, 2008; 111(7): 3553 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Du, W.-H. Zhou, F.-T. Yan, X.-Y. Zhu, Y.-Y. He, J.-Y. Yang, and D.-J. Li Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells Hum. Reprod., September 1, 2007; 22(9): 2528 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-R. Du, L. Dong, W.-H. Zhou, F.-T. Yan, and D.-J. Li Cyclosporin A Improves Pregnancy Outcome by Promoting Functions of Trophoblasts and Inducing Maternal Tolerance to the Allogeneic Fetus in Abortion-Prone Matings in the Mouse Biol Reprod, May 1, 2007; 76(5): 906 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Gonzalez-Pacheco, J. J. P. Deudero, M. C. Castellanos, M. A. Castilla, M. V. Alvarez-Arroyo, S. Yague, and C. Caramelo Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1395 - H1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Minami, M. Miura, W. C. Aird, and T. Kodama Thrombin-induced Autoinhibitory Factor, Down Syndrome Critical Region-1, Attenuates NFAT-dependent Vascular Cell Adhesion Molecule-1 Expression and Inflammation in the Endothelium J. Biol. Chem., July 21, 2006; 281(29): 20503 - 20520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Minguillon, B. Morancho, S.-J. Kim, M. Lopez-Botet, and J. Aramburu Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-{beta}1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-{beta}1 J. Leukoc. Biol., May 1, 2005; 77(5): 748 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Mason, R. Steinberg, E. A. Lidington, A. R. Kinderlerer, M. Ohba, and D. O. Haskard Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-{alpha}/{epsilon} (PKC{alpha}/{epsilon})-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A J. Biol. Chem., October 1, 2004; 279(40): 41611 - 41618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Hesser, X. H. Liang, G. Camenisch, S. Yang, D. A. Lewin, R. Scheller, N. Ferrara, and H.-P. Gerber Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells Blood, July 1, 2004; 104(1): 149 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kim, S. M. Lessner, Y. Sakurai, and Z. S. Galis Cyclophilin A as a Novel Biphasic Mediator of Endothelial Activation and Dysfunction Am. J. Pathol., May 1, 2004; 164(5): 1567 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Castilla, F. Neria, G. Renedo, D. S. Pereira, F. R. Gonzalez-Pacheco, S. Jimenez, P. Tramon, J. J. P. Deudero, M. V. A. Arroyo, S. Yague, et al. Tumor-induced endothelial cell activation: role of vascular endothelial growth factor Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1170 - C1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caramelo, Ma. V. Alvarez-Arroyo, S. Yague, Y. Suzuki, Ma. A. Castilla, L. Velasco, F. R. Gonzalez-Pacheco, and A. Tejedor Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward Nephrol. Dial. Transplant., February 1, 2004; 19(2): 285 - 288. [Full Text] [PDF]
|
|
|
|
|
|
E. N. Johnson, Y. M. Lee, T. L. Sander, E. Rabkin, F. J. Schoen, S. Kaushal, and J. Bischoff NFATc1 Mediates Vascular Endothelial Growth Factor-induced Proliferation of Human Pulmonary Valve Endothelial Cells J. Biol. Chem., January 10, 2003; 278(3): 1686 - 1692. [Abstract] [Full Text] [PDF]
|
|